PROCTER & GAMBLE HYGIENE AND HEALTH CARE LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16,169 INR | +0.29% |
|
+1.40% | -6.82% |
| 03-26 | Analysis-In India's sizzling stock market, consumer stocks rise 18% but are laggards | RE |
| 03-18 | Indian Equities Start Week in Black, Aided by Major Auto and Metal Firms | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Personal Products
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -6.82% | 6.29B | C | ||
| +10.07% | 381B | C- | ||
| +14.18% | 74.67B | A+ | ||
| -16.59% | 62.59B | A- | ||
| +0.82% | 52.86B | B+ | ||
| -12.40% | 36.11B | - | ||
| +3.54% | 33.57B | B- | ||
| +7.92% | 17.29B | A- | ||
| +6.30% | 14.75B | B | ||
| -8.65% | 10.82B | C+ |
Investor Rating
Trading Rating
-
ESG Refinitiv
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
-
Potential Price Target
-
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
- Stock Market
- Equities
- PGHH Stock
- Ratings Procter & Gamble Hygiene and Health Care Limited
